Monoclonal Antibody to Phospholipase A2, Lipoprotein Associated (LpPLA2)
| Code | Size | Price |
|---|
| MAA867Hu22-20ul | 20ul | £86.00 |
Quantity:
| MAA867Hu22-100ul | 100ul | £160.00 |
Quantity:
| MAA867Hu22-200ul | 200ul | £216.00 |
Quantity:
| MAA867Hu22-1ml | 1ml | £494.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
PLA2G7; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2; Phospholipase A2, Lipoprotein Associated
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Phospholipase A2 Group VII
Potency (Clone Number):
D6
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;1:500-2000;<br/>Immunohistochemistry: 5-20ug/mL;1:50-200;<br/>Immunocytochemistry: 5-20ug/mL;1:50-200;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Phospholipase A2, Lipoprotein Associated (LpPLA2) | RPA867Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||